Expert consensus on clinical trials for use of systemic therapy in patients with hepatocellular carcinoma undergoing surgical and locoregional therapies

By afschroeder • September 25, 2026

Yarchoan M, Llovet JM, Kelley RK, Finn R, Parikh ND, Tabrizian P, Burgoyne AM, Agopian VG, Sanford NN, Tran Cao HS, Padia SA, Vogel A, Lewandowski RJ, Kirema GR, Lin R, Mehta N, Sapisochin G, Yopp A, Villanueva A, Halazun K, Pinato DJ, Kim E, Heimbach JK, Pillai A, Salem R, El-Khoueiry A, Singal AG. Expert consensus on clinical trials for use of systemic therapy in patients with hepatocellular carcinoma undergoing surgical and locoregional therapies. Gut. 2026 Sep 24:gutjnl-2026-339505. doi: 10.1136/gutjnl-2026-339505. Epub ahead of print. PMID: 42785981.

Tags: adjuvant treatment, clinical trials, Hematology/Oncology, Hepatocellular carcinoma, immunotherapy, Publications

Immune biomarkers of response and resistance to ipilimumab and nivolumab in metastatic castration-resistant prostate cancer

Tsimberidou AM, Cabanski CR, Drakaki A, Khalil DN, Siddiqui BA, Basu S, Okrah K, Da Silva DM, Gautam S, Alayli FA, Schachter M, Fairchild J,[...]

Response to Zhang and Shi

Ji J, Cohen HJ, Sedrak MS. Response to Zhang and Shi. J Natl Cancer Inst. 2026 Oct 12:djag380. doi: 10.1093/jnci/djag380. Epub ahead of print. PMID:[...]

177Lu-Prostate-specific Membrane Antigen Prior to Stereotactic Ablative Radiotherapy in Oligorecurrent Prostate Cancer: Secondary and Exploratory End Point Results from the Randomized Phase 2 LUNAR Trial

Kishan AU, Wilhalme H, Felix C, Enke J, Ali FZ, Nabong R, Juarez-Casillas JE, Flores K, Ma TM, Ludwig V, Nakayama M, Ells Z, Dahlbom[...]